Authors' Response
T o the Editor: Guandalini and Newland express concern that other diagnoses of the upper gastrointestinal tract will be missed if the diagnosis of celiac disease (CD) is made without performing an upper endoscopy. We thank the authors for pointing out this issue and the journal for affording us the chance to respond.
The authors report the results of their retrospective chart review with endoscopic findings in 115 children with anti-TG2 antibody concentrations >10 times the upper limit of normal. According to the new European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) guidelines on the diagnosis of CD, these patients would qualify for the option to omit the biopsies under the following conditions in addition to the high TG2 antibody concentrations: symptoms suggestive of CD, positive anti-endomysial antibodies in a second blood sample, HLA-DQ2 or -DQ8 positivity, and informed consent after discussion with a pediatric gastroenterologist (1). In 11 of 115 patients, abnormal findings were reported; however, we would consider some of them less relevant or part of the celiac pathology. For example, Helicobacter pylori infection does not need to be treated in the absence of erosions and ulcerations (2) . Chronic superficial or lymphocytic gastritis are common findings in children with untreated CD (3, 4) and should resolve with a gluten-free diet. The remaining patients had different types of esophagitis, one of them with eosinophilic infiltrations. No information is provided as to whether the diagnosis of esophagitis was based on macroscopic findings with mucosal breaks (erosions, ulcerations) or histology only.
Untreated CD causes dysmotility with delayed gastric emptying because of reduced secretion of gastrointestinal hormones in the presence of enteropathy. This may predispose to gastroesophageal reflux and esophagitis, but again, dysmotility will resolve after normalization of the small bowel mucosa with a gluten-free diet. In addition, it is unclear how many unselected control children would show any esophageal pathology. The Kalixanda study reports findings in 1000 population-based adults who underwent upper endoscopy with multiple biopsies. Even in the absence of any symptoms, 9.5% were found to have erosive esophagitis. This proportion reached 20% to 36% in individuals complaining of occasional to daily symptoms (5) . In the same study, definite or probable eosinophilic esophagits (EoE) was identified in 1.1%, and eosinophilic infiltrations were related to reflux esophagitis (6) . It has been suggested that EoE is more frequent than expected in patients with CD; however, a recent meta-analysis on incidence and prevalence of EoE in children reported a prevalence ranging from 1.1% to 5.1% in CD compared with 2.1% to 4.9% in children who underwent endoscopy for abdominal pain (7) .
The data point to the dilemma that a concurrent disease may be responsible for the symptoms leading to medical attention, and CD essentially may be asymptomatic. Symptomatology and clinical judgment are important elements of the ESPGHAN guidelines. In cases in which the type of gastrointestinal symptoms (mainly abdominal pain) indicates the possibility of additional pathology, it is at the discretion of the managing physician to perform an endoscopy already at the beginning of the clinical workup. Although CD cannot be diagnosed after starting the diet, an endoscopical search for additional pathology can be performed at any later time in those children whose symptoms do not respond to a gluten-free diet. This would still spare a majority from the invasive procedure.
In conclusion, we believe that the findings observed by Guandalini and Newland do not justify changing the ESPGHAN guidelines and the option to omit duodenal biopsies. At the same time, we strongly support their recommendation to follow-up on these children receiving a gluten-free diet and evaluate those in whom symptoms do not resolve.
Antitumor Necrosis Factor, Infliximab, and Adalimumab: Use With Caution in Eosinophilic Bowel Disease
T o the Editor: We read the article by Turner et al (1) with great interest and concern because it proposes that ''infliximab and adalimumab may be effective in refractory idiopathic eosinophilic enterocolitis'' (EEC). Our concerns lie in the lack of diagnostic clarity, uncertainty of clinical efficacy of the treatments, the suggested chronic use of medications with significant potential adverse effects, and uncertain therapeutic rationale. Histological features defining eosinophilic gastrointestinal disease beyond the esophagus remain difficult to define, and parameters defining EEC are even less clear. The authors quote 3 review references that provide no diagnostic clarity regarding EEC (2) (3) (4) . Because images of histological slides were not included, the histological parameters used to define EEC in the presented patients remain unclear.
We are uncertain whether the pain experienced can be clearly ascribed to the duodenal eosinophilia or vice versa because it relates to the 5 responsive patients. Three patients showed a decrease in duodenal eosinophil numbers, 1 remained the same, and 1 was not reassessed. Although 3 patients experienced reduction in pain and a decrease in eosinophilia, the cause and effect are difficult to ascertain because there is a significant placebo effect associated with abdominal pain. Systemic and topical steroids, medications known to decrease mucosal eosinophilia, did not reduce symptoms in 3 of 5 of these patients. A further confounder is the long time intervals that occurred in some of the patients between initiating the biological treatments and obtaining the mucosal findings; this raises the question of how the mucosa appeared at the beginning of biological treatment.
The long treatment duration and lack of documented toxicity monitoring are concerning because they appear to support the use of these medications at ''higher doses than practiced for IBD'' for up to 6 years without significant risk (5) . Although there is a small body of literature suggesting that TNF-a is a therapeutic target for eosinophilic esophagitis, evidence supporting its role in other eosinophilic gastrointestinal diseases is lacking (6) .
The authors suggest that additional studies are warranted; however, we propose that until more supportive evidence becomes available, these medications be used with extreme caution for welldefined time periods and accompanied by close monitoring for adverse effects. refractory to multiple aggressive therapies and there is no reason to believe that suddenly a placebo effect will be so striking only with anti-TNF.
We do not suggest that anti-TNF should be routinely used in EEC. We fully agree with Furuta et al that a trial of anti-TNF treatment in EEC should only be considered at this time in severe and resistant cases, accompanied by monitoring for adverse effects as we practice in classic IBD. Response should be assessed closely (including repeated biopsies) to ensure that the drug is indeed effective. It is also reasonable to plan exit strategies in the responsive cases. Indeed, the literature is eagerly awaiting level I evidence for effective therapies and ''diagnostic clarity'' of EEN, but until then, we must still treat our patients, making use of the bestavailable evidence. Ã Dan Turner and y Craig Friesen Ã Jerusalem, Israel y Kansas City, MO
